期刊文献+

人乳腺癌融合蛋白疫苗HSP65-HER2的表达、纯化及活性检测 被引量:1

原文传递
导出
摘要 目的:在大肠杆菌中表达、并纯化获得高纯度的融合蛋白疫苗HSP65-HER2。方法:经过酶切和序列分析后,将pET-28a-HSP65-HER2重组质粒转化Ecoli(BL21)中,经IPTG诱导产生6-his tag-HSP65-HER2融合蛋白,并通过Ni Sepharose 4B和Superdex G-25纯化。以纯化的重组融合蛋白免疫小鼠,取脾细胞经体外诱导后,采用CTL活性检测其活性。结果:成功的表达、纯化获得了高纯度的HSP65-HER2融合蛋白,CTL活性检测结果表明具有生物学活性。结论:获得了高纯度的HSP65-HER2融合蛋白,并证明其具有免疫学活性,为进一步研究其生物学活性奠定了基础。
出处 《中国妇幼保健》 CAS 北大核心 2010年第6期824-826,共3页 Maternal and Child Health Care of China
  • 相关文献

参考文献8

  • 1McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer- epidemiology, risk factors, and genetics [J]. BMJ Clin Res Ed, 2000, 321 (7261): 624.
  • 2Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER - 2/neu oncogene [J].Science, 1987, 235 (4785) : 177.
  • 3Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J].Nature, 2003, 421 (6924): 756.
  • 4Yip YL, Ward RL Anti - ErbB - 2 monoclonal antibodies and ErbB - 2 -direct vaccines[J]. Cancer Immunology Immunotherapy, 2002, 50 (11): 569.
  • 5Amin A, Benavides LC. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study 1-01 and 1-02 [J].Cancer Immunol Immunotherapy, 2008, 14 (3) : 797.
  • 6George E, Peoples Jennifer M, Gurney Matthew T et al. Clinical trial results of a HER2/neu ( E75 ) vaccine to prevent recurrence in high - risk breast cancer patients [J]. Journal of Clinical Oncology, 2005, 23 (30): 7536.
  • 7Mittendorf EA, Storrer CE, Foley RJ et al. Evaluation of the HER2/ neu - derived peptide GP2 for use in a peptide - based breast cancer vaccine trial [J] . Cancer, 2006, 106 (11) : 2309.
  • 8王雪薇,王建华.Triton X-114萃取法去除脑膜炎球菌荚膜多糖中的内毒素[J].中国生物制品学杂志,2008,21(5):438-441. 被引量:16

二级参考文献11

  • 1金礼琴,叶灯凤.胞磷胆碱钠注射液制备工艺的改进[J].中国生化药物杂志,2004,25(6):357-358. 被引量:2
  • 2唐守万,孔亮,欧俊杰,邹汉法.柱亲和介质用于内毒素去除的研究[J].分析化学,2006,34(4):455-458. 被引量:11
  • 3蔡慧丽.生物技术药品分离纯化过程中内毒素的去除[J].海峡药学,2006,18(2):157-159. 被引量:7
  • 4汪家政 范明.蛋白质技术手册[M].北京:科学出版社,2002(第一版).51-54.
  • 5Tsukushi Y,Kido N,Saeki K,et al.Characteristic biological activities of lipopolysaccharides form Sinorhizobium and Mesorhizobium.J Endotoxin Res,2004,10(1):25-31.
  • 6Aida Y,Pabst MJ.Removal of endotoxin from protein solutions by phase separation using Triton X-114.J Immunol Methods,1990,132(2):191-195.
  • 7Adam O,Vercellone A,Paul F,et al.A nondegradative route for the removal of endotoxin from exopolysaccharides.Anal Biochem,1995,225 (2):321-327.
  • 8Amoureux MC,Hegyi E,Le D,et al.A new method for removing endotoxin from plasama using hemocompatible affinity chromatography technology,applicable for extracorporeal treatment of septic patients.J Endotoxin Res,2004,10(2):85-95.
  • 9Amoureux MC,Rajapake N,Hegyi E,et al.Endotoxin removal from whole blood by a novel adsorption resin:efficiency and hemocompatibility.Int J Artif Organs,2004,27(6);480-487.
  • 10Bell CM,Cuo K,Wendel HP.Endotoxin removal from albumin and saline solutions.Int J Artif Organs,2007,30(7):589-593.

共引文献15

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部